Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18912061 | INSECT NEUROPEPTIDES 6 | October 2024 | May 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18906616 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | October 2024 | September 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18660826 | CELL PENETRATING PEPTIDE | May 2024 | October 2025 | Allow | 17 | 1 | 0 | No | No |
| 18426692 | READY-TO-USE BIVALIRUDIN COMPOSITIONS | January 2024 | September 2025 | Allow | 20 | 1 | 1 | No | No |
| 18411838 | ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME | January 2024 | February 2026 | Abandon | 25 | 2 | 1 | No | No |
| 18405731 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | January 2024 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18513026 | NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18506719 | INTRANASAL DESMOPRESSIN ADMINISTRATION | November 2023 | December 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18496597 | METHOD FOR ADJUSTING A PARENTERAL SUPPORT (PS) VOLUME IN A HUMAN SUBJECT | October 2023 | January 2025 | Abandon | 15 | 2 | 1 | No | No |
| 18491976 | INSECT NEUROPEPTIDES 6 | October 2023 | July 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18241549 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | September 2023 | February 2026 | Abandon | 30 | 2 | 1 | No | No |
| 18349855 | FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A pH-TRIGGERED POLYPEPTIDE | July 2023 | January 2025 | Allow | 18 | 1 | 0 | No | No |
| 18144387 | PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF | May 2023 | March 2025 | Allow | 22 | 1 | 1 | No | No |
| 18308695 | POLYPEPTIDE AND APPLICATION THEREOF IN BONE REPAIR | April 2023 | January 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18128799 | IDENTIFYING NEW THERAPEUTIC AGENTS | March 2023 | August 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18120648 | DEUTERATED TETRAPEPTIDES THAT TARGET MITOCHONDRIA | March 2023 | October 2025 | Abandon | 31 | 1 | 1 | No | No |
| 18172938 | METHOD OF REDUCING BISPECIFIC T CELL ENGAGER OR CHIMERIC ANTIGEN RECEPTOR T CELL MEDIATED CYTOKINE RELEASE SYNDROME USING INTERLEUKINS-4, -10, OR A FUSION PROTEIN THEREOF | February 2023 | December 2024 | Abandon | 22 | 0 | 1 | Yes | No |
| 18168570 | METHODS AND COMPOSITIONS FOR TREATING HYPOGLYCEMIC DISORDERS | February 2023 | May 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18103694 | CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOF | January 2023 | October 2024 | Allow | 21 | 2 | 1 | No | No |
| 18160807 | METHODS FOR PREVENTING FUNGAL INFECTIONS | January 2023 | July 2025 | Abandon | 30 | 1 | 1 | No | No |
| 18094167 | CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | January 2023 | October 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 18060523 | READY-TO-USE BIVALIRUDIN COMPOSITIONS | November 2022 | January 2024 | Allow | 13 | 2 | 1 | No | No |
| 18060529 | READY-TO-USE BIVALIRUDIN COMPOSITIONS | November 2022 | January 2024 | Allow | 13 | 1 | 1 | No | No |
| 17996330 | SETD7 EPIGENETIC MODULATORS | October 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17894545 | METHOD FOR TREATMENT OF TYPE-1 DIABETES IN A SUBJECT IN NEED THEREOF | August 2022 | September 2024 | Abandon | 25 | 2 | 1 | Yes | No |
| 17820013 | ANTIMICROBIAL AND ANTICANCER PEPTIDES & CONJUGATES AND COMPOSITIONS, METHODS, ARTICLES & KITS RELATING THERETO | August 2022 | April 2025 | Abandon | 32 | 3 | 1 | No | No |
| 17817537 | SINGLE DOSE METHODS FOR PREVENTING AND TREATING FUNGAL INFECTIONS | August 2022 | April 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17866905 | METHOD FOR PREPARING ETELCALCETIDE HYDROCHLORIDE | July 2022 | October 2024 | Allow | 27 | 3 | 1 | No | No |
| 17855372 | COLLAGEN MIMICS | June 2022 | April 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17809940 | SYNTHETIC PEPTIDE SP2 AND APPLICATION THEREOF | June 2022 | July 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17854647 | CELL PENETRATING PEPTIDE | June 2022 | February 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 17846990 | PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOF | June 2022 | October 2023 | Abandon | 16 | 2 | 1 | No | No |
| 17843079 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | June 2022 | July 2025 | Abandon | 37 | 2 | 1 | No | No |
| 17841929 | ISOLATED PEPTIDE, ANTI-CANCER MEDICINAL COMPOSITION INCLUDING THE SAME AND METHOD OF SPECIFICALLY REDUCING OR INHIBITING ACTIVITIES OF CANCER CELLS USING THE SAME | June 2022 | October 2023 | Allow | 16 | 1 | 0 | No | No |
| 17663188 | CYCLOSPORIN COMPOSITIONS | May 2022 | January 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17730960 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | April 2022 | May 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17770122 | Peptides with cell damage protection activity and liposomial formulations | April 2022 | December 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17767302 | CYCLIC PEPTIDE COMPOUND CONTAINING PIPERAZIC ACID, METHOD OF PRODUCING SAME, AND USES OF SAME | April 2022 | February 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17709917 | PROTEIN-WIDE MODIFICATION OF ASPARTATES AND GLUTAMATES | March 2022 | April 2025 | Abandon | 37 | 3 | 1 | No | No |
| 17656347 | Synthetic peptide sp4 and use thereof | March 2022 | November 2023 | Allow | 19 | 1 | 1 | No | No |
| 17698526 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | March 2022 | November 2023 | Allow | 20 | 1 | 1 | No | No |
| 17698531 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | March 2022 | August 2023 | Allow | 17 | 0 | 1 | No | No |
| 17691576 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | March 2022 | November 2023 | Allow | 21 | 1 | 1 | No | No |
| 17638038 | SELF-ASSEMBLING PEPTIDES, PREPARATION METHODS, SELF-ASSEMBLING PEPTIDE FORMULATIONS AND USE | February 2022 | January 2026 | Abandon | 47 | 2 | 1 | No | No |
| 17677162 | COMPOSITION FOR TREATING CANCER EXPRESSING SPARC | February 2022 | December 2023 | Abandon | 22 | 1 | 1 | No | No |
| 17635595 | TREATMENT | February 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17650894 | PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME | February 2022 | September 2024 | Abandon | 31 | 3 | 1 | No | No |
| 17582445 | ANTIGENIC POLYPEPTIDES AND METHODS OF USE THEREOF | January 2022 | August 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17627035 | EVOLVED BOTULINUM NEUROTOXINS AND USES THEREOF | January 2022 | February 2026 | Allow | 49 | 2 | 1 | No | No |
| 17573317 | GIPR-AGONIST COMPOUNDS | January 2022 | October 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17564893 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | December 2021 | May 2024 | Abandon | 29 | 3 | 1 | No | No |
| 17620433 | PROCESS FOR THE MANUFACTURE OF GLUCAGON | December 2021 | December 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17554134 | COLLAGEN-BASED MENISCUS IMPLANTS | December 2021 | February 2026 | Allow | 50 | 5 | 0 | No | No |
| 17618416 | INTRANASAL ADMINISTRATION OF MEROTOCIN FOR IMPROVING LACTATION | December 2021 | April 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17548044 | PEPTIDE AND USE THEREOF | December 2021 | June 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17547076 | AMINO DEPROTECTION USING 3-(DIETHYLAMINO)PROPYLAMINE | December 2021 | February 2023 | Allow | 14 | 1 | 1 | Yes | No |
| 17530142 | ENDOLYSIN VARIANT | November 2021 | September 2023 | Allow | 22 | 1 | 1 | Yes | No |
| 17527807 | COMPOSITIONS FOR DIAGNOSIS, PREVENTION, OR TREATMENT OF FATTY LIVER DISEASE | November 2021 | January 2026 | Allow | 50 | 5 | 1 | Yes | No |
| 17525023 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | November 2021 | August 2023 | Allow | 21 | 1 | 1 | No | No |
| 17603311 | METHODS OF OCULAR TREATMENT USING AN ENGINEERED DIMERIC FRAGMENT OF HEPATOCYTE GROWTH FACTOR | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17486602 | THERAPEUTIC COMPOUNDS AND METHODS | September 2021 | March 2023 | Allow | 18 | 1 | 1 | No | No |
| 17410819 | SYNTHETIC HEME-CONTAINING MOLECULES AND THEIR USE | August 2021 | September 2024 | Abandon | 37 | 2 | 1 | Yes | No |
| 17400629 | THERAPEUTIC AGENT OF UREMIA CONTAINING ALARIN AS THE MAIN INGREDIENT | August 2021 | February 2023 | Allow | 18 | 1 | 0 | No | No |
| 17397539 | MOSQUITOCIDAL XENORHABDUS, LIPOPEPTIDE AND METHODS | August 2021 | June 2024 | Abandon | 34 | 2 | 1 | Yes | No |
| 17310536 | DECORATED INCLUSION BODY AND USES THEREOF | August 2021 | June 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17389671 | ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME | July 2021 | October 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17377338 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | July 2021 | January 2024 | Allow | 30 | 1 | 1 | No | No |
| 17421605 | CELL-PENETRATING PEPTIDES | July 2021 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17358734 | PHARMACEUTICAL COMPOSITIONS OF GHRH ANALOGS AND USES THEREOF | June 2021 | July 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17414103 | MITOCHONDRIA-TARGETING PEPTIDES | June 2021 | February 2025 | Allow | 44 | 3 | 1 | Yes | No |
| 17348043 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | June 2021 | October 2024 | Allow | 40 | 3 | 1 | Yes | No |
| 17333609 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | May 2021 | July 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17330798 | INTRANASAL DESMOPRESSIN ADMINISTRATION | May 2021 | January 2024 | Abandon | 60 | 1 | 1 | No | No |
| 17294527 | Composition and Method for Regulating Migration of Immune Cells | May 2021 | October 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17294011 | TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/P25 AS TREATMENT FOR CANCER | May 2021 | August 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17319250 | FLAGELLIN COMPOSITIONS AND USES | May 2021 | July 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17243660 | Methods and Compositions for Oral Administration of Exenatide | April 2021 | January 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17240278 | MATRIPTASE AND U-PLASMINOGEN ACTIVATOR SUBSTRATES AND OTHER CLEAVABLE MOIETIES AND METHODS OF USE THEREOF | April 2021 | September 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17238932 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING LUNG CANCER | April 2021 | July 2023 | Allow | 26 | 1 | 1 | No | No |
| 17285188 | METHOD AND SYSTEM FOR TREATING CANCER UTILIZING TINAGL1 | April 2021 | March 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17227206 | SELENIUM-CHELATING PEA OLIGOPEPTIDE, AND PREPARATION METHOD AND USE THEREOF | April 2021 | January 2025 | Allow | 45 | 5 | 1 | Yes | No |
| 17283997 | INHIBITORS OF PICK1 AND USES THEREOF | April 2021 | March 2025 | Abandon | 47 | 3 | 1 | Yes | No |
| 17282514 | USE OF VEGF AT MULTIPLE DOSES TO ENHANCE PERMEABILITY OF BLOOD BRAIN BARRIER | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17281862 | Peptide Possessing Mesenchymal-Stem-Cell Mobilizing Activity | March 2021 | December 2024 | Abandon | 45 | 3 | 1 | No | No |
| 17281942 | TELEOST INVARIANT CHAIN CANCER VACCINE | March 2021 | January 2026 | Allow | 59 | 4 | 1 | No | No |
| 17213472 | NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | March 2021 | August 2023 | Allow | 29 | 2 | 1 | Yes | No |
| 17280067 | NONAPEPTIDE PREVENTING INCREASED HYPERPERMEABILITY OF VASCULAR ENDOTHELIUM | March 2021 | November 2023 | Abandon | 31 | 2 | 1 | No | No |
| 17276101 | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | March 2021 | March 2024 | Allow | 36 | 3 | 1 | Yes | No |
| 17199342 | MERS-COV INHIBITOR PEPTIDES | March 2021 | October 2023 | Abandon | 31 | 2 | 1 | Yes | No |
| 17270787 | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY | February 2021 | March 2026 | Abandon | 60 | 3 | 1 | Yes | No |
| 17173917 | TANDEM REPEAT CANCER-TARGETING PEPTIDES FOR MOLECULAR CONJUGATION OR ENGINEERING AND USES THEREOF IN CANCER THERANOSTICS | February 2021 | February 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17267914 | PROTEOGENOMIC-BASED METHOD FOR IDENTIFYING TUMOR-SPECIFIC ANTIGENS | February 2021 | January 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17172202 | Fusion Protein Between Short Form Rod-Derived Cone Viability Factor and a Hydrophilic Peptide | February 2021 | August 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 17265684 | COMBINATION THERAPIES COMPRISING TIM-3-BASED CHIMERIC PROTEINS | February 2021 | June 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17264277 | CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | January 2021 | July 2023 | Abandon | 30 | 2 | 1 | No | No |
| 17154097 | HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS | January 2021 | October 2022 | Abandon | 20 | 0 | 1 | No | No |
| 17153423 | HETEROCHIRAL PEPTIDE-COMPLEX AND COMPOSITION FOR MEASURING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY RESIDUAL DIPOLAR COUPLING CONTAINING SELF-ASSEMBLED INTERMEDIATES OF HETEROCHIRAL PEPTIDE-COMPLEX | January 2021 | November 2023 | Allow | 34 | 3 | 1 | Yes | No |
| 17149583 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | January 2021 | September 2025 | Allow | 56 | 4 | 1 | Yes | No |
| 17259914 | PEPTOID-PEPTIDE MACROCYCLES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | January 2021 | July 2024 | Allow | 42 | 4 | 1 | Yes | No |
| 17136285 | CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS | December 2020 | July 2022 | Abandon | 18 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NIEBAUER, RONALD T.
With a 54.5% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NIEBAUER, RONALD T works in Art Unit 1658 and has examined 341 patent applications in our dataset. With an allowance rate of 52.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner NIEBAUER, RONALD T's allowance rate of 52.8% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NIEBAUER, RONALD T receive 2.16 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by NIEBAUER, RONALD T is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +37.2% benefit to allowance rate for applications examined by NIEBAUER, RONALD T. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.5% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 12.6% of cases where such amendments are filed. This entry rate is in the 13% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 57.7% of appeals filed. This is in the 31% percentile among all examiners. Of these withdrawals, 40.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 90.0% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.